Clinical trials: Nonalcoholic Steatohepatitis
Obesity, Nonalcoholic Steatohepatitis
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects.
- Trial name
- NCT04561245
- Testing
- ALT-801
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
NASH - Nonalcoholic Steatohepatitis
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled, adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of TERN-201 in patients with non-cirrhotic NASH.
- Trial name
- NCT04897594
- Testing
- TERN-201
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Obese
Changes in Intrahepatic Lipids With Exercise
Individuals with obesity and particular type 2 diabetes have abnormally high levels of fat in liver cells and are at increased risk for cardiovascular and liver-related mortality.
- Trial name
- NCT02181270
- Testing
- high intensity exercise, continuous moderate exercise
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
This multi-center, double-blind, randomized, placebo-controlled study will evaluate the change in liver fat content, pharmacokinetics and safety of RO5093151 in patients with non-alcoholic fatty liver disease.
- Trial name
- NCT01277094
- Testing
- RO5093151
- Where
- 4 sites in Austria, Germany
- Volunteers
- 82 people
- Sponsor
- Hoffmann-La Roche
Non-Alcoholic Fatty Liver Disease
The Influence of SARS-CoV-2 Lifestyle Changes on Non-alcoholic Fatty Liver Disease Evolution
Unhealthy lifestyle represents a key element fueling the non-alcoholic fatty liver disease (NAFLD) onset and worsening. The investigators aimed to evaluate the effects of confinement-related lifestyle changes experienced during…
- Trial name
- NCT05416970
- Testing
- SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES
- Where
- Italy
- Volunteers
- 122 people
- Sponsor
- University of Campania Luigi Vanvitelli
NAFLD - Non Alcoholic Fatty Liver Disease
Association Between Non-alcoholic Fatty Liver Disease and Iron Status
The investigators hypothesize that low iron storages protects from and down-grades non-alcoholic fatty liver disease. The aim of the study is to show the association between the severity of Non-alcoholic fatty liver disease to…
- Trial name
- BAFLA (NCT01307254)
- Testing
- blood analysis
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Ornit Cohen
Type2 Diabetes, Non-Alcoholic Fatty Liver Disease
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases
- Trial name
- NCT03910361
- Testing
- Evogliptin, Pioglitazone
- Where
- 7 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- Dong-A ST Co., Ltd.
Nonalcoholic Fatty Liver
Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
This study is a prospective, observational, single-center, short-term cross-sectional study to assess the repeatability and reproducibility of a set of specified MRI quantitative biomarkers.
- Trial name
- NCT05081427
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
NASH (Non-Alcoholic Steatohepatitis)
Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis
VENS is a multicenter, randomized, double-masked, placebo parallel controlled trial to evaluate the efficacy and safety of treatment with vitamin E softgel in non diabetic adults with NASH compared to treatment with placebo in…
- Trial name
- NCT02962297
- Testing
- Vitamin E softgel
- Where
- 15 sites in China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Medicine Co., Ltd.
Non Alcoholic Fatty Liver Disease
Study to Investigate the Effect of L. Lactis CKDB001 Administration on Liver Aminotransferases in Subjects With NAFLD
A study for evaluating the safety and efficacy of L. lactis CKDB001 on liver aminotransferases in subjects with nonalcoholic fatty liver disease
- Trial name
- NCT07378280
- Testing
- Probiotics (L. lactis CKDB001)
- Where
- South Korea
- Volunteers
- 95 people
- Sponsor
- Chuncheon Sacred Heart Hospital
NAFLD
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
The investigators will conduct a proof-of-principle 4-weeks low-calorie diet (LCD) intervention study in low birth weight (LBW) subjects and normal birth weight (NBW) controls with documented (MR scan) liver fat content equal to…
- Trial name
- NCT05842850
- Testing
- Caloric restriction intervention, No intervention
- Where
- 2 sites in Denmark
- Volunteers
- 8 people
- Sponsor
- Steno Diabetes Center Copenhagen
Non Alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis…
- Trial name
- NCT04880187
- Testing
- AXA1125
- Where
- 75 sites in United States, Australia and 5 more
- Volunteers
- 273 people
- Sponsor
- Axcella Health, Inc
Fatty Liver, Nonalcoholic
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
The aim of the current study is to evaluate the safety and efficay of cilostazol in treatment of patients with fatty liver disease. Several previous reports have shown that cilostazol ameliorates lipid imbalances in NAFLD.
- Trial name
- NCT04761848
- Testing
- Cilostazol 50 MG
- Where
- Egypt
- Sponsor
- Sadat City University
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease
Ultrasound Method to Measure Fibrosis of the Liver in Children
HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) provide accurate quantitative measurements that can be used to stage liver fibrosis in pediatric patients with chronic liver disease.
- Conditions
- Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coinfection, HBV
- Trial name
- NCT02086708
- Testing
- Shear Wave sonoelastography
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Fatty Liver
A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this study is to determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in patients.
- Trial name
- NCT00799578
- Testing
- Cysteamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Joel Lavine
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate the safety and tolerability of firsocostat in adults with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02856555
- Testing
- Firsocostat
- Where
- 36 sites in United States
- Volunteers
- 127 people
- Sponsor
- Gilead Sciences
Nonalcoholic Fatty Liver Disease
Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent countries. It may progress to cirrhosis and liver cancer. At present, there is no approved drug for NAFLD.
- Trial name
- NCT00868933
- Testing
- Low glycemic index dietary intervention program, simple lifestyle advice
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Chinese University of Hong Kong
Non-Alcoholic Fatty Liver Disease
Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population
To build a Registry of volunteers by inviting them to get a LiverMultiScan(LMS)and collecting their contact information to seek interest in participating in future studies.
- Trial name
- DFWRegistry (NCT04336618)
- Testing
- Liver MultiScan
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Perspectum
Non-alcoholic Steatohepatitis (NASH)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis
- Trial name
- NCT04607655
- Testing
- GB1211
- Sponsor
- Galecto Biotech AB
Fatty Liver, Liver Dysfunction
The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease
The role of Helicobacter pylori(HP)in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is controversial.
- Conditions
- Fatty Liver, Liver Dysfunction, Insulin Resistance
- Trial name
- NCT01876108
- Testing
- H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Tehran University of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.